Radiogenomics mapping noninvasively determines important relationships between the molecular genotype and imaging phenotype of various tumors, allowing advances in both clinical care and cancer research. While early work has shown its technical feasibility, here we extend 1 radiogenomic mapping to a locoregional level that can account for the molecular heterogeneity of tumors. To achieve this, our data processing pipeline relies on three main steps: 1) the use of multi-omics data fusion to generate a set of 100 interpretable gene modules, 2) the use of patch-based image analysis (specifically of contrast-enhanced T1-weighted weighted MR images) combined with Generalized Linear Models (GLM) to establish potential links between module expressions and local MR signal, and 3) the use of expression heatmaps based on GLMs decision values to explore visualization of tumor molecular heterogeneity. The performance of the proposed approach was evaluated using a leave-one-patient-out crossvalidation method as well as a separate validation data set. The top performing models were based on a small set of 20 features and yielded Area Under the receiver operating characteristic Curve (AUC) above 0.65 on the validation cohort for eight modules. Next, we demonstrate the clinical and biological interpretation of four modules using molecular expression heatmaps superimposed on clinical radiographic images, showing the potential for assessing tumor molecular heterogeneity and the utility of this method for precision treatment in clinical decision making and imaging surveillance.
Introduction
Radiogenomics is an burgeoning field of science that reveals important relationships between molecular properties of tumors and their macroscopic appearance on radiographic imaging used in the clinical setting. It is defined by the linking of quantitative image features with molecular data and holds the potential to be readily translatable to clinical decision making by the identification 2 of imaging biomarkers that can accurately predict underlying tumor biology and the efficacy of treatment. The actual translation of this approach to the clinic is feasible as medical imaging is a standard part of the routine diagnostic work-up and surveillance of cancer patients.
It is well known that there is genomic heterogeneity between tumors and also within individual tumors 1, 2 . However, the only way to determine tumor genotype is through invasive surgical sampling, and given the spatial inhomogeneity of genomic expression within a tumor, information about the local in vivo microenvironment 3 and locoregional tumor precursor cells-of-origin 4 can be lost in biopsies. The creation of radiogenomic maps bypasses the need for surgical sampling in order to understand a tumor lesions' underlying biology and the changes that may result from treatment intervention. The application of radiogenomic maps has been demonstrated in hepatocellular carcinoma 5 , lung cancer [6] [7] [8] , and gliomas (particularly high grade gliomas such as glioblastoma) [9] [10] [11] [12] . The aforementioned analyses utilized human-based semantic descriptions of the tumor appearance on imaging such as the Visually AcceSsible Rembrandt Images (VASARI) features 13 , while others utilized global imaging features such as the extent of tumor associated vasogenic edema, regions of non-enhancing tumor, enhancement and necrosis from semi-automatic segmentations of tumors with imaging analysis software 12 , and lastly, global extraction of more classical radiomics quantitative features extracted across the gross tumor volume 14 . In contrast, radiogenomics models in the two latter studies demonstrate significant but average performance.
Importantly, there exists a significant body of literature confirming that molecular expression is variable within a single tumor lesion and, therefore, studies which assume homogeneity across the entire volume of tumor may lead to an oversimplified and inaccurate radiogenomics model.
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To this end, recent studies investigated a locoregional approach based on manually delineated necrotic, enhancing, edematous or nonenhancing tumor regions 15, 16 . Beig et al. 15 observed that the localized radiomics features that were most informative of hypoxia distinguished between short-and long-term survivors. Similarly, Hu et al. 16 revealed significant imaging correlations with local expression of molecular markers in glioblastoma. This study had a low sample size of only 13 tumors due to the need for multiple localized image-guided biopsies and the unique challenge in the clinical setting of brain tumors requiring neurosurgical intervention which may not be clinically indicated.
In this study, we implement radiogenomics mapping that accounts for the locoregional heterogeneity of brain tumors as observed on imaging and link signature image features with their molecular profiles. We use an automated and localized image analysis by dividing the tumors into patches.
The latter is based on the hypothesis that confined tumor habitats have distinct molecular and imaging signatures when compared to larger tumor volumes 17 . Moreover, this provides the opportunity to estimate local molecular profiles and further relate them using a holistic approach to assess brain tumors. We focus this study on human glioblastoma (GBM), which is the most common and most lethal form of primary brain cancer in adults, accounting for 16% of all primary tumors and 82% of all malignant tumors within the central nervous system 18 . GBM occurs most frequently within the 45-70 year age group with a mean age of 63 years in the USA, and is 1.6 times more prevalent in males than females 18 . GBMs are typically fast-growing and infiltrative tumors that are invariably fatal. With current standardized treatment, the median survival rate for patients with glioblastoma is just 14.6 months, and the five-year overall survival rate is 4.7% 18 .
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Our work shows that locoregional modeling of Magnetic Resonance (MR) images of GBM can capture gene module expression and heterogeneity within this tumor.
Methods
Study populations: multi-omics and MR imaging data. We used two distinct and publicly available radiogenomics datasets: we first used patients from The Cancer Genome Atlas (TCGA) glioblastoma data set 19 to develop locoregional radiogenomics maps, and then validated them using the REpository of Molecular BRAin Neoplasia DaTa (REMBRANDT) dataset 20, 21 . We used multi-omics molecular data from TCGA project including gene expression, DNA methylation and DNA copy number data 19 . The gene expression data were produced using Agilent microarrays for GBM. Preprocessing was done by log-transformation and quantile normalization of the arrays 22, 23 . The DNA methylation data were generated using the Illumina Infinium Human Methylation 27 Bead Chip. DNA methylation was quantified using β-values ranging from 0 to 1 according to the DNA methylation levels. We removed CpG sites with more than 10% of missing values in all samples. We used the 15-K nearest neighbor algorithm to estimate the remaining missing values in the data set 24 . Finally, the copy number data we used were produced by the Agilent Sure Print G3
Human CGH Microarray Kit 1M×1M platform. This platform has high redundancy at the gene level, but we observed high correlation between probes matching the same gene. Therefore, probes matching the same gene were merged by taking the average. For all data sources, gene annotation was translated to official gene symbols based on the HUGO Gene Nomenclature Committee identifiers. Next, TCGA samples were analyzed in batches and a significant batch effect was observed 5 based on a one-way analysis of variance in most data modes. We applied Combat to adjust for these effects 25 . For the REMBRANT cohort only gene expression data was available produced by Affymetrix GeneChip Human Genome U133 Plus 2.0 microarrays archived by G-DOC 26 . Preprocessing was done as previously reported 27 . Briefly the RMA algorithm was used for preprocessing the microarray data 28 . Matched Magnetic Resonance (MR) images were available for both the TCGA and REMBRANDT cohorts from The Cancer Imaging Archive (TCIA) 29 . We used only pre-surgical, gadolinium-enhanced, axial T1-weighted images with a slice thickness equal to or less than 3 mm. This resulted in a total of 84 and 47 patients for the TCGA and REMBRANDT cohorts, respectively.
Multi-omics data fusion. We used AMARETTO, a multi-omics data fusion framework creating gene expression modules by integrating DNA methylation, DNA copy number and gene expression data [30] [31] [32] using the TCGA data and created the gene expression modules on the REMBRANDT data set. To generate a gene regulatory module network of glioma, we first applied AMARETTO on the preprocessed copy number, DNA methylation and gene expression data. DNA methylation data was modeled using MethylMix [33] [34] [35] [36] [37] identifying only differentially methylated and transcriptionally predictive genes. Genomic Identification of Significant Targets in Cancer (GISTIC) was used to identify the recurrently amplified and deleted genes using DNA copy number data.
Both lists of genes were used in combination with RNA gene expression data to develop 100 AMARETTO gene modules 30, 31, 38 linking the genomic-and epigenomics-driven genes to their targets. Modules were annotated using gene set enrichment analysis. We used the following gene- 42 . Modules were then created for the REMBRANDT data set using the regulator and target gene expression values.
Modules were represented by the mean average expression of all target genes in each module. Note that only gene expression data is necessary to represent the modules, and no DNA methylation or DNA copy number data is needed. All module values were standardized to have mean zero and standard deviation equal to one. Next, we divided the tumor region into patches according to the following procedure ( Figure 1 ).
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The ROIs were divided into overlapping circular patches with a radius of r=12 pixels (6mm) in axial slices and center x. r = 6mm was chosen as a trade-off between locality and the wealth of visual information encompassed in the patches 44 . The patches were randomly positioned while keeping a minimum distance between patch centers equal to their radius r. The latter process was repeated was carried out on a patch basis. Separate models were built for boundary and core patches. The class membership y q,i (i.e., over-versus under-expressed gene module q) of the patch i expressed in terms of its feature vector η i was estimated using a Generalized Linear Model (GLM) 48 as
where the decision value y q,i = [−1, 1] for under-and over-expression of q in a training patch i.
Results
AMARETTO modules capture major glioblastoma pathways. We used AMARETTO to build 100 gene expression modules based on 426 TCGA patients. Each module was further annotated using gene set enrichment analysis (Supplementary Table 1 ) resulting in modules enriched in key biological pathways including apoptosis, cell cycle, immune response and angiogenesis ( Figure 2 ).
Next, we validated these modules using the gene expression data of the REMBRANDT validation cohort. Approximately two thirds of the modules have high R-square and module homogeneity in the REMBRANDT cohort (Supplementary Table 2 ).
Radiogenomics modeling. For each module the Area Under the ROC Curve (AUC) was measured based on the GLM's continuous decision values. AUCs were computed for predictions based on either core or boundary patches ( Figure 1 and Table 1 ). AUCs were averaged over 50 repetitions of the random patch positioning. Performance comparison and combination of intensity and texture features show that texture-based models cannot accurately predict the presence or absence of gene modules, and that combining them with intensity harms the predictive performance in most cases (Supplementary Table 3 ). Therefore, we focused on intensity-based models. AUCs above 0.65 for all three validation setups were observed for modules 70 and 90 when the model was based on core patches as well as for modules 36 and 84 when based on boundary patches. AUCs above 0.65 with both TCGA LOPO and REMBRANDT validation were observed for modules 32, 24 and 45 when the model was based on core patches as well as for module 45 when based on boundary patches.
Note that the latter was best predicted using core patches. (Table 1) . We can, however, study the relation between predictive performance and the thresholds on the decision values (i.e., the output of the GLM model as defined in Eq. 1) to avoid forcing the model to provide a decision when patches have a weak absolute decision value. This shows that the AUC as a function of the threshold on the absolute decision values monotonously increases as a function of the predictive performance for most modules (Figure 5) , suggesting that the decision values of the proposed models allow for a true identification of the local patches that are involved in the gene module expression. This indirectly validates the association between locoregional image patches and gene expression (Figures 3 and 4) .
Discussion
We proposed a radiogenomics approach to study the intricate relationships between imaging phenotypes of GBMs and their molecular properties. Our approach relies on three main steps, including: (i) multi-omics data fusion to generate interpretable gene modules, (ii) locoregional image analysis and supervised multivariate models to establish multivariate models between MR image features and module expressions and (iii) the construction of module expression heatmaps to visualize intratumoral molecular heterogeneity as image overlays. When compared to previous works on radiogenomics of GBMs, we used automated image analysis with a finer grained level to take into account the locoregional heterogeneity of tumors and their molecular profiles. Secondly, the multi-omics clustering algorithm AMARETTO applied to the TCGA data allowed us to reduce data dimensionality while generating interpretable gene modules (Figure 2 ). Two thirds of the modules were also consistently observed on the validation cohort (REMBRANDT) with high R-square and module homogeneity (Supplementary Table 2 ). The proposed locoregional radiomics modeling was found to yield predictive AUCs on both cohorts for 15 modules (Table 1) . For five of them, the model trained on TCGA could be used directly to predict their expression in REMBRANDT. For the other seven, significant AUCs were observed for both TCGA and REMBRANDT LOPO, but 13 not when directly applying the model from TCGA on REMBRANDT. The number of features used in the models was at most 20 (i.e., the normalized intensity histogram bins), whereas the number of instances (i.e., patches) was in the range of 8,000 to 20,000. This ensured a number of instances far superior to the dimensionality of the model, thus limiting drastically the risk of overfitting as well as the risk of fortuitous discoveries and associations.
Next, we were able to associate biologically meaningful and clinically relevant interpretations for the best predicted gene modules. In particular, module 32 is involved in the maintenance of glioma stem cells, module 11 is a core cell cycle module and module 93 is involved in the receptor tyrosine kinase pathways. Finally, module 84 is linked to BCAN, a highly expressed gene in gliomas promoting the growth and motility of brain tumor cells. It is therefore meaningful to observe that module 84 is best predicted using patches extracted from the boundaries of the tumors and that BCAN expression can be deduced from MR imaging. Moreover, it has not escaped our attention that two drug targets are among the regulators of modules that can be predicted from imaging:
TNFRSF1A and ERBB3. TNFRSF1A is a target of VB-111 an antiangiogenic agent that showed effectiveness in phase 1 trials 51 and is currently evaluated in a phase 3 trial (NCT02511405).
Secondly, ERBB3 is part of the EGFR family, and an emerging cancer drug target 52 . Previous results have shown that targeting EGFR and EGFRvIII in glioblastoma results in compensatory mechanisms in other family members including ERBB3, therefore targeting ERBB3 is potentially equally important 53, 54 .
Texture features were not found to carry relevant information related to local heterogeneity (Supplementary Tables 3). While the latter is contradictory to the findings of 15 and 16 showing that texture attributes are correlated with the genotype of the tumor, a fundamental difference in our approach is the use of very localized image instances as patches with a radius of 12 pixels (6mm).
It is difficult to extract rich texture information on these small ROIs, where the number of possible digital spatial frequencies is small and the influence of neighboring objects (e.g., skull or cortical gyri) is dominant 55 . Moreover, these previous reports used other texture feature types (i.e. Laws, Gabor, Haralick, local binary patterns and the discrete orthonormal Stockwell transform), which can also account the discrepant findings 15 and 16 .
Next, the exploratory expression heatmaps are the first attempts to reveal the relationship between cancer driver gene module expressions and local imaging patterns using only global gene expression patterns. They provide the opportunity to identify imaging patterns on contrast-enhanced T1-weighted images that are most related to the expression of a given module (Figure 3 and 4) .
When used for gene modules that obtained both high predictive performance and biological interpretation, the proposed visualization opens up avenues for assessing and quantifying personalized response to treatment targeting precise genes by observing the presence and heterogeneity of the radiogenomics map.
Finally, we studied the relationship between thresholded GLM's absolute decision values and the predictive performance to validate the predictions and the associated heatmaps. This avoided forcing models to provide a decision when the patches have low absolute decision values and showed that with increasing threshold value, the model performance consistently increased ( Figure 5 ). This suggests that the proposed expression heatmaps are truly highlighting regions with high under-or over-expression of the modules. Combing our work with parallel efforts focusing on multiple sampling points (e.g., guided by the proposed expression heatmaps) in order to obtain local gene expression for validation promises to provide additional validation of the locoregional MR imaging patterns reflecting molecular properties of GBM 16 . Taken together our radiogenomics framework provides future research direction for treatment allocation, treatment follow-up and treatment monitoring by using MR imaging phenotypes that reflect molecular properties of brain tumors.
To conclude, we extended radiogenomics mapping to a locoregional level that can account for the molecular heterogeneity of GBM tumors. In addition to the demonstration of the feasibility of the latter with an external validation set, we built a radiogenomic map for clinically relevant gene modules with illustrative support from molecular expression heatmaps superimposed on medical images.
53 Table 1 . The observed performance increase suggests that the model is able to truly identify the instances that are involved in the gene module expression.
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